Global vascular guidelines on the management of chronic limb-threatening ischemia

, Michael S. Conte (Lead / Corresponding author), Andrew W. Bradbury, Philippe Kolh, John V. White, Florian Dick, Robert Fitridge, Joseph L. Mills, Jean-Baptiste Ricco, Kalkunte R. Suresh, M. Hassan Murad

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.
Original languageEnglish
Pages (from-to)S1-S109.e33
JournalEuropean Journal of Vascular and Endovascular Surgery
Volume58
Issue number1
Early online date28 May 2019
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Blood Vessels
Ischemia
Extremities
Guidelines
Amputation
Foot
Veins
Clinical Trials
Preventive Medicine
Regenerative Medicine
Gangrene
Mortality
Peripheral Arterial Disease
Toes
Smoking Cessation
Critical Care
Cell- and Tissue-Based Therapy
Genetic Therapy
Antihypertensive Agents
Prostaglandins

Keywords

  • Bypass surgery
  • Chronic limb-threatening ischemia
  • Critical limb ischemia
  • Diabetes
  • Endovascular intervention
  • Evidence-based medicine
  • Foot ulcer
  • Peripheral artery disease
  • Practice guideline

Cite this

Conte, Michael S. ; Bradbury, Andrew W. ; Kolh, Philippe ; White, John V. ; Dick, Florian ; Fitridge, Robert ; Mills, Joseph L. ; Ricco, Jean-Baptiste ; Suresh, Kalkunte R. ; Murad, M. Hassan. / Global vascular guidelines on the management of chronic limb-threatening ischemia. In: European Journal of Vascular and Endovascular Surgery. 2019 ; Vol. 58, No. 1. pp. S1-S109.e33.
@article{252be89b4abf4e8492aa17e4bdf7db20,
title = "Global vascular guidelines on the management of chronic limb-threatening ischemia",
abstract = "Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.",
keywords = "Bypass surgery, Chronic limb-threatening ischemia, Critical limb ischemia, Diabetes, Endovascular intervention, Evidence-based medicine, Foot ulcer, Peripheral artery disease, Practice guideline",
author = "Conte, {Michael S.} and Bradbury, {Andrew W.} and Philippe Kolh and White, {John V.} and Florian Dick and Robert Fitridge and Mills, {Joseph L.} and Jean-Baptiste Ricco and Suresh, {Kalkunte R.} and Murad, {M. Hassan} and Victor Aboyans and Murat Aksoy and Vlad-adrian Alexandrescu and David Armstrong and Nobuyoshi Azuma and Jill Belch and Michel Bergoeing and Martin Bjorck and Nabil Chakf{\'e} and Stephen Cheng and Joseph Dawson and Debus, {Eike Sebastian} and Andrew Dueck and Susan Duval and Eckstein, {Hans Henning} and Roberto Ferraresi and Raghvinder Gambhir and Mauro Gargiulo and Patrick Geraghty and Steve Goode and Bruce Gray and Wei Guo and Gupta, {Prem Chand} and Robert Hinchliffe and Prasad Jetty and Kimihiro Komori and Lawrence Lavery and Wei Liang and Robert Lookstein and Matthew Menard and Sanjay Misra and Tetsuro Miyata and Greg Moneta and Prado, {Jose Antonio Munoa} and Alberto Munoz and Paolini, {Juan Esteban} and Manesh Patel and Frank Pomposelli and Richard Powell and Peter Robless",
note = "Copyright {\circledC} 2019 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.ejvs.2019.05.006",
language = "English",
volume = "58",
pages = "S1--S109.e33",
journal = "European Journal of Vascular and Endovascular Surgery",
issn = "1078-5884",
publisher = "Elsevier",
number = "1",

}

Conte, MS, Bradbury, AW, Kolh, P, White, JV, Dick, F, Fitridge, R, Mills, JL, Ricco, J-B & Suresh, KR & Murad, MH 2019, 'Global vascular guidelines on the management of chronic limb-threatening ischemia', European Journal of Vascular and Endovascular Surgery, vol. 58, no. 1, pp. S1-S109.e33. https://doi.org/10.1016/j.ejvs.2019.05.006

Global vascular guidelines on the management of chronic limb-threatening ischemia. /; Conte, Michael S. (Lead / Corresponding author); Bradbury, Andrew W.; Kolh, Philippe; White, John V.; Dick, Florian; Fitridge, Robert; Mills, Joseph L.; Ricco, Jean-Baptiste; Suresh, Kalkunte R.; Murad, M. Hassan.

In: European Journal of Vascular and Endovascular Surgery, Vol. 58, No. 1, 01.07.2019, p. S1-S109.e33.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Global vascular guidelines on the management of chronic limb-threatening ischemia

AU - Conte, Michael S.

AU - Bradbury, Andrew W.

AU - Kolh, Philippe

AU - White, John V.

AU - Dick, Florian

AU - Fitridge, Robert

AU - Mills, Joseph L.

AU - Ricco, Jean-Baptiste

AU - Suresh, Kalkunte R.

AU - Murad, M. Hassan

AU - Aboyans, Victor

AU - Aksoy, Murat

AU - Alexandrescu, Vlad-adrian

AU - Armstrong, David

AU - Azuma, Nobuyoshi

AU - Belch, Jill

AU - Bergoeing, Michel

AU - Bjorck, Martin

AU - Chakfé, Nabil

AU - Cheng, Stephen

AU - Dawson, Joseph

AU - Debus, Eike Sebastian

AU - Dueck, Andrew

AU - Duval, Susan

AU - Eckstein, Hans Henning

AU - Ferraresi, Roberto

AU - Gambhir, Raghvinder

AU - Gargiulo, Mauro

AU - Geraghty, Patrick

AU - Goode, Steve

AU - Gray, Bruce

AU - Guo, Wei

AU - Gupta, Prem Chand

AU - Hinchliffe, Robert

AU - Jetty, Prasad

AU - Komori, Kimihiro

AU - Lavery, Lawrence

AU - Liang, Wei

AU - Lookstein, Robert

AU - Menard, Matthew

AU - Misra, Sanjay

AU - Miyata, Tetsuro

AU - Moneta, Greg

AU - Prado, Jose Antonio Munoa

AU - Munoz, Alberto

AU - Paolini, Juan Esteban

AU - Patel, Manesh

AU - Pomposelli, Frank

AU - Powell, Richard

AU - Robless, Peter

N1 - Copyright © 2019 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.

AB - Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.

KW - Bypass surgery

KW - Chronic limb-threatening ischemia

KW - Critical limb ischemia

KW - Diabetes

KW - Endovascular intervention

KW - Evidence-based medicine

KW - Foot ulcer

KW - Peripheral artery disease

KW - Practice guideline

UR - http://www.scopus.com/inward/record.url?scp=85066829614&partnerID=8YFLogxK

U2 - 10.1016/j.ejvs.2019.05.006

DO - 10.1016/j.ejvs.2019.05.006

M3 - Article

VL - 58

SP - S1-S109.e33

JO - European Journal of Vascular and Endovascular Surgery

JF - European Journal of Vascular and Endovascular Surgery

SN - 1078-5884

IS - 1

ER -